Remove 2006 Remove Competition Remove Sales
article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Boston is emerging as one of the hottest startup cities in the country, which is great news for sales professionals. These companies are all backed by venture capital and are currently hiring in sales roles. This is by no means an exhaustive list, but here are some great companies to consider for your next sales job. ProfitWell.

Sales 76
article thumbnail

Merck defends blockbuster Januvia franchise from patent challenge

pharmaphorum

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. billion in the first half of 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

Meulenbelt highlighted “the desire to have broader launches is very good,” since under the current model, if OMP companies can make a major part of their sales in a limited number of markets they are unlikely to launch elsewhere, limiting patient access. Maarten has significant competition law experience in a variety of sectors.

article thumbnail

Will A.I. Replace the Medical Sales Workforce and Surgeons? With Edouard Saget

Evolve Your Success

In the changing balance between innovation and tradition, medical sales succeeds with personal connection, persistence, and the commitment to link technology and patient care. For today’s episode, we have Edouard Saget to discuss the big question: Will AI replace medical sales workforce and surgeons? Tune in to find out!

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Currently, 40 biosimilars are FDA-approved and 25 have launched, whereas the EMA has approved 86 biosimilars since 2006. Further, there remains scepticism on the efficacy and safety of biosimilars.

article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings. However, new MS drugs like Novartis ’ Gilenya, were going to soon enter the market and increase competition within the MS therapeutic landscape.

article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Conducting internal pre-sale checks and looking at your level of compliance and licenses is a vital exercise. She joined NSF in 2017.

Pharma 109